Anti-PD-1 therapies (e.g., pembrolizumab) enhance IFN-γ-producing B cells and TLS formation, showing 33%–55% ORR in MSI-H CRC (André et al., 2022). This evidence concerns the gene PDCD1 and colorectal carcinoma.